ISAVUCONAZOLE ADVZ (Boucher & Muir Pty Ltd)
Product name
ISAVUCONAZOLE ADVZ
Sponsor
Date registered
Evaluation commenced
Decision date
Approval time
115 (255 working days)
Active ingredients
isavuconazonium sulfate
Registration type
New generic medicine
Indication
Isavuconazole ADVZ is indicated in adults and paediatric patients from 1 year of age for the treatment of
- invasive aspergillosis
- mucormycosis in patients for whom amphotericin B is inappropriate (see Section 4.4 Special warnings and precautions for use and Section 5.1 Pharmacodynamicproperties)
Consideration should be given to official guidance on the appropriate use of antifungal agents.